In April 2008, Chelsea acquired exclusive global rights from Active Biotech to the I-3D portfolio of therapeutic compounds, targeting autoimmune diseases and transplant rejection.
The I-3D portfolio consists of an extensive library of orally active therapeutic compounds that have demonstrated inhibition of Dihydroorotate dehydrogenase (DHODH) activity during preclinical testing.
Inhibition of DHODH is the rate-limiting step in de novo pyrimidine biosynthesis, which is required for the proliferation of T-cells during clonal expansion. Potential treatment settings for drug candidates in this library include transplant rejection, rheumatoid arthritis, psoriasis and systemic lupus erythematosus. More than 15 compounds in this portfolio have been isolated and undergone extensive preclinical modeling.